glp-1/gip medication Understand Dual Agonist Tirzepatide and Its Effect on Current Weight Loss Therapy GIP + GLP-1 Weight-Loss Injections

Patients were followed from the index date until first occurrence of treatment discontinuation, emigration, death or the end of the study period (31 December 2022)

The report from Katz and colleagues comes less than a year after another report in the Journal of the American Medical Association suggested a link between semaglutide use and nonarteritic anterior ischemic optic neuropathy (NAION), which is a condition that causes sudden vision loss

Conclusion Bridging the gap between promising preclinical results and clinically viable, patient-friendly therapies, especially achieving effective oral delivery, will be critical for the widespread adoption of peptides in future healthcare

Some studies showed prevention benefits even in the absence of metabolic changes.[ref][ref] Studies are showing positive effects on cognitive function and possibly reduced (or delayed) dementia with GLP-1s

Semaglutide for managing overweight and obesity (TA875): Chapter 1 Recommendations

2.How can we guarantee quality